Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Henry Schein Inc (HSIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,992,550
  • Shares Outstanding, K 156,950
  • Annual Sales, $ 11,572 M
  • Annual Income, $ 506,780 K
  • 36-Month Beta 1.00
  • Price/Sales 0.99
  • Price/Cash Flow 17.20
  • Price/Book 3.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.57 +9.10%
on 12/29/17
77.25 -1.75%
on 01/17/18
+4.89 (+6.89%)
since 12/22/17
3-Month
65.28 +16.27%
on 11/14/17
83.73 -9.35%
on 10/26/17
-6.95 (-8.39%)
since 10/23/17
52-Week
65.28 +16.27%
on 11/14/17
93.50 -18.82%
on 06/09/17
-1.78 (-2.29%)
since 01/23/17

Most Recent Stories

More News
What to Expect From Quest Diagnostics (DGX) in Q4 Earnings

Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.

DGX : 102.66 (-0.88%)
HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BAX : 69.96 (-0.34%)
BIO : 257.74 (+1.21%)
Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?

IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.

HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
IDXX : 181.43 (+0.27%)
BIO : 257.74 (+1.21%)
Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

HSIC : 76.04 (-0.48%)
BSX : 27.83 (+0.43%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

EW : 125.29 (+0.63%)
HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?

Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.

ZBH : 125.18 (-0.81%)
HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.

HSIC : 76.04 (-0.48%)
ILMN : 244.12 (-0.44%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?

Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.

HSIC : 76.04 (-0.48%)
TMO : 215.85 (+0.25%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?

Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.

HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)
ALGN : 275.36 (+3.09%)
Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

ABT : 59.56 (-0.02%)
HSIC : 76.04 (-0.48%)
MYGN : 39.52 (-0.90%)
BIO : 257.74 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Henry Schein, a Fortune 500(R) company, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 475,000 customers worldwide, including dental practices and laboratories, physician...

See More

Key Turning Points

2nd Resistance Point 76.96
1st Resistance Point 76.69
Last Price 76.04
1st Support Level 75.90
2nd Support Level 75.38

See More

52-Week High 93.50
Fibonacci 61.8% 82.72
Fibonacci 50% 79.39
Fibonacci 38.2% 76.06
Last Price 76.04
52-Week Low 65.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.